Figure 3.

Prevalence of human papillomavirus (HPV) types 16 or 18 among heterosexual men who reported to have a steady partner, by age of the steady partner and vaccine‐eligibility of the steady partner. *Vaccine‐eligibility of the steady partner was based on the reported age of the steady partner in a specific PASSYON study round and the Dutch national immunization program. None of the steady partners of ≥22 years had been eligible according to the national immunization program in the Netherlands.